{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:39:09Z","timestamp":1794242349450,"version":"4.9.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270796, 82070776,82200849 and 82370761"],"award-info":[{"award-number":["82270796, 82070776,82200849 and 82370761"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","award":["2022RC3071"],"award-info":[{"award-number":["2022RC3071"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ40872"],"award-info":[{"award-number":["2023JJ40872"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04260-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:33:42Z","timestamp":1751366022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role and mechanism of TSC in kidney diseases: a literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Qiulin","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinguo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longkai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"4260_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/s0140-6736(13)60439-0","volume":"382","author":"K-U Eckardt","year":"2013","unstructured":"Eckardt K-U, Coresh J, Devuyst O, Johnson RJ, K\u00f6ttgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382:158\u201369. https:\/\/doi.org\/10.1016\/s0140-6736(13)60439-0.","journal-title":"Lancet"},{"key":"4260_CR2","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/s2214-109x(16)30308-4","volume":"5","author":"AJ Dare","year":"2017","unstructured":"Dare AJ, Fu SH, Patra J, Rodriguez PS, Thakur JS, Jha P. Renal failure deaths and their risk factors in India 2001\u201313: nationally representative estimates from the million death study. Lancet Global Health. 2017;5:e89\u201395. https:\/\/doi.org\/10.1016\/s2214-109x(16)30308-4.","journal-title":"Lancet Global Health"},{"key":"4260_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41581-018-0095-2","volume":"15","author":"C Kurts","year":"2019","unstructured":"Kurts C, Meyer-Schwesinger C. Protecting the kidney against autoimmunity and inflammation. Nat Rev Nephrol. 2019;15:66\u20138. https:\/\/doi.org\/10.1038\/s41581-018-0095-2.","journal-title":"Nat Rev Nephrol"},{"key":"4260_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41581-019-0110-2","volume":"15","author":"PM-K Tang","year":"2019","unstructured":"Tang PM-K, Nikolic-Paterson DJ, Lan H-Y. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15:144\u201358. https:\/\/doi.org\/10.1038\/s41581-019-0110-2.","journal-title":"Nat Rev Nephrol"},{"key":"4260_CR5","doi-asserted-by":"publisher","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","volume":"2","author":"EP Henske","year":"2016","unstructured":"Henske EP, J\u00f3\u017awiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Reviews Disease Primers. 2016;2:16035. https:\/\/doi.org\/10.1038\/nrdp.2016.35.","journal-title":"Nat Reviews Disease Primers"},{"key":"4260_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-z","volume":"75","author":"ECTS Consortium","year":"1993","unstructured":"Consortium ECTS. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305\u201315. https:\/\/doi.org\/10.1016\/0092-8674(93)90618-z.","journal-title":"Cell"},{"key":"4260_CR7","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1007\/s11010-021-04088-3","volume":"476","author":"K Mallela","year":"2021","unstructured":"Mallela K, Kumar A. Role of TSC1 in physiology and diseases. Mol Cell Biochem. 2021;476:2269\u201382. https:\/\/doi.org\/10.1007\/s11010-021-04088-3.","journal-title":"Mol Cell Biochem"},{"key":"4260_CR8","doi-asserted-by":"publisher","unstructured":"Barone S, Zahedi K, Brooks M, Henske E, Yang Y, Zhang E, et al. Kidney intercalated cells and the transcription factor FOXi1 drive cystogenesis in tuberous sclerosis complex. Proc Natl Acad Sci. 2021;118(e2020190118). https:\/\/doi.org\/10.1073\/pnas.2020190118.","DOI":"10.1073\/pnas.2020190118"},{"key":"4260_CR9","doi-asserted-by":"publisher","unstructured":"Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991;66:792\u20136. https:\/\/doi.org\/10.1016\/s0025-6196(12)61196-3.","DOI":"10.1016\/s0025-6196(12)61196-3"},{"key":"4260_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/dmcn.13352","volume":"59","author":"S Amin","year":"2017","unstructured":"Amin S, Lux A, Calder N, Laugharne M, Osborne J, O\u2019Callaghan F. Causes of mortality in individuals with tuberous sclerosis complex. Dev Med Child Neurol. 2017;59:612\u20137. https:\/\/doi.org\/10.1111\/dmcn.13352.","journal-title":"Dev Med Child Neurol"},{"key":"4260_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/s0140-6736(08)61279-9","volume":"372","author":"P Curatolo","year":"2008","unstructured":"Curatolo P, Bombardieri R, Jozwiak S, Tuberous sclerosis. Lancet. 2008;372:657\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(08)61279-9.","journal-title":"Lancet"},{"key":"4260_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M van Slegtenhorst","year":"1997","unstructured":"van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805\u20138. https:\/\/doi.org\/10.1126\/science.277.5327.805.","journal-title":"Science"},{"key":"4260_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.mcn.2007.02.007","volume":"35","author":"S Yasui","year":"2007","unstructured":"Yasui S, Tsuzaki K, Ninomiya H, Floricel F, Asano Y, Maki H, et al. The TSC1 gene product Hamartin interacts with NADE. Mol Cell Neurosci. 2007;35:100\u20138. https:\/\/doi.org\/10.1016\/j.mcn.2007.02.007.","journal-title":"Mol Cell Neurosci"},{"key":"4260_CR14","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-z","volume":"75","author":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","year":"1993","unstructured":"Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305\u201315. https:\/\/doi.org\/10.1016\/0092-8674(93)90618-z.","journal-title":"Cell"},{"key":"4260_CR15","doi-asserted-by":"publisher","first-page":"7965","DOI":"10.1128\/mcb.24.18.7965-7975.2004","volume":"24","author":"Y Li","year":"2004","unstructured":"Li Y, Inoki K, Guan KL. Biochemical and functional characterizations of small GTPase rheb and TSC2 GAP activity. Mol Cell Biol. 2004;24:7965\u201375. https:\/\/doi.org\/10.1128\/mcb.24.18.7965-7975.2004.","journal-title":"Mol Cell Biol"},{"key":"4260_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.21542","volume":"118","author":"J Jozwiak","year":"2006","unstructured":"Jozwiak J. Hamartin and tuberin: working together for tumour suppression. Int J Cancer. 2006;118:1\u20135. https:\/\/doi.org\/10.1002\/ijc.21542.","journal-title":"Int J Cancer"},{"key":"4260_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/s0898-6568(03)00040-8","volume":"15","author":"VP Krymskaya","year":"2003","unstructured":"Krymskaya VP. Tumour suppressors Hamartin and tuberin: intracellular signalling. Cell Signal. 2003;15:729\u201339. https:\/\/doi.org\/10.1016\/s0898-6568(03)00040-8.","journal-title":"Cell Signal"},{"key":"4260_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1006\/abbi.2001.2682","volume":"398","author":"DJ Noonan","year":"2002","unstructured":"Noonan DJ, Lou D, Griffith N, Vanaman TC. A calmodulin binding site in the tuberous sclerosis 2 gene product is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and Lymphangioleiomyomatosis. Arch Biochem Biophys. 2002;398:132\u201340. https:\/\/doi.org\/10.1006\/abbi.2001.2682.","journal-title":"Arch Biochem Biophys"},{"key":"4260_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-006-9134-0","volume":"79","author":"J Jozwiak","year":"2006","unstructured":"Jozwiak J, Wlodarski P. Hamartin and tuberin modulate gene transcription via beta-catenin. J Neurooncol. 2006;79:229\u201334. https:\/\/doi.org\/10.1007\/s11060-006-9134-0.","journal-title":"J Neurooncol"},{"key":"4260_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","volume":"25","author":"CC Dibble","year":"2015","unstructured":"Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 2015;25:545\u201355. https:\/\/doi.org\/10.1016\/j.tcb.2015.06.002.","journal-title":"Trends Cell Biol"},{"key":"4260_CR21","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1681\/asn.2008111186","volume":"20","author":"W Lieberthal","year":"2009","unstructured":"Lieberthal W, Levine JS. The role of the mammalian target of Rapamycin (mTOR) in renal disease. J Am Soc Nephrol. 2009;20:2493\u2013502. https:\/\/doi.org\/10.1681\/asn.2008111186.","journal-title":"J Am Soc Nephrol"},{"key":"4260_CR22","doi-asserted-by":"publisher","first-page":"15637","DOI":"10.1038\/ncomms15637","volume":"8","author":"D Bakula","year":"2017","unstructured":"Bakula D, M\u00fcller AJ, Zuleger T, Takacs Z, Franz-Wachtel M, Thost AK, et al. WIPI3 and WIPI4 \u03b2-propellers are scaffolds for LKB1-AMPK-TSC signalling circuits in the control of autophagy. Nat Commun. 2017;8:15637. https:\/\/doi.org\/10.1038\/ncomms15637.","journal-title":"Nat Commun"},{"key":"4260_CR23","doi-asserted-by":"publisher","first-page":"102812","DOI":"10.1016\/j.jbc.2022.102812","volume":"299","author":"W Wang","year":"2023","unstructured":"Wang W, Zhang Z, Zhao M, Wang Y, Ge Y, Shan L. Zinc-finger protein CXXC5 promotes breast carcinogenesis by regulating the TSC1\/mTOR signaling pathway. J Biol Chem. 2023;299:102812. https:\/\/doi.org\/10.1016\/j.jbc.2022.102812.","journal-title":"J Biol Chem"},{"key":"4260_CR24","doi-asserted-by":"publisher","first-page":"751892","DOI":"10.3389\/fcell.2021.751892","volume":"9","author":"U Rehbein","year":"2021","unstructured":"Rehbein U, Prentzell MT, Cadena Sandoval M, Heberle AM, Henske EP, Opitz CA, et al. The TSC Complex-mTORC1 axis: from lysosomes to stress granules and back. Front Cell Dev Biol. 2021;9:751892. https:\/\/doi.org\/10.3389\/fcell.2021.751892.","journal-title":"Front Cell Dev Biol"},{"key":"4260_CR25","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/ajt.15320","volume":"19","author":"H Dai","year":"2019","unstructured":"Dai H, Thomson AW. The other mTOR complex: new insights into mTORC2 immunobiology and their implications. Am J Transpl. 2019;19:1614\u201321. https:\/\/doi.org\/10.1111\/ajt.15320.","journal-title":"Am J Transpl"},{"key":"4260_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","volume":"47","author":"CC Dibble","year":"2012","unstructured":"Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, et al. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell. 2012;47:535\u201346. https:\/\/doi.org\/10.1016\/j.molcel.2012.06.009.","journal-title":"Mol Cell"},{"key":"4260_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ncb847","volume":"4","author":"X Gao","year":"2002","unstructured":"Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol. 2002;4:699\u2013704. https:\/\/doi.org\/10.1038\/ncb847.","journal-title":"Nat Cell Biol"},{"key":"4260_CR28","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1172\/jci133264","volume":"130","author":"Y Xie","year":"2020","unstructured":"Xie Y, Zhao Y, Shi L, Li W, Chen K, Li M, et al. Gut epithelial TSC1\/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer. J Clin Invest. 2020;130:2111\u201328. https:\/\/doi.org\/10.1172\/jci133264.","journal-title":"J Clin Invest"},{"key":"4260_CR29","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1038\/ncomms5696","volume":"5","author":"L Zhu","year":"2014","unstructured":"Zhu L, Yang T, Li L, Sun L, Hou Y, Hu X, et al. TSC1 controls macrophage polarization to prevent inflammatory disease. Nat Commun. 2014;5:4696. https:\/\/doi.org\/10.1038\/ncomms5696.","journal-title":"Nat Commun"},{"key":"4260_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41419-024-06538-4","volume":"15","author":"M Ni","year":"2024","unstructured":"Ni M, Qiu J, Liu G, Sun X, Zhu W, Wu P, et al. Loss of macrophage TSC1 exacerbates sterile inflammatory liver injury through inhibiting the AKT\/MST1\/NRF2 signaling pathway. Cell Death Dis. 2024;15:146. https:\/\/doi.org\/10.1038\/s41419-024-06538-4.","journal-title":"Cell Death Dis"},{"key":"4260_CR31","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1182\/blood.2022018619","volume":"141","author":"X Xie","year":"2023","unstructured":"Xie X, Zhang W, Xiao M, Wei T, Qiu Y, Qiu J, et al. TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice. Blood. 2023;141:3184\u201398. https:\/\/doi.org\/10.1182\/blood.2022018619.","journal-title":"Blood"},{"key":"4260_CR32","doi-asserted-by":"publisher","first-page":"e51228","DOI":"10.7759\/cureus.51228","volume":"15","author":"MA Almazmomi","year":"2023","unstructured":"Almazmomi MA, Esmat A, Naeem A. Acute kidney injury: definition, management, and promising therapeutic target. Cureus. 2023;15:e51228. https:\/\/doi.org\/10.7759\/cureus.51228.","journal-title":"Cureus"},{"key":"4260_CR33","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1038\/s41418-019-0336-3","volume":"26","author":"Y Gui","year":"2019","unstructured":"Gui Y, Lu Q, Gu M, Wang M, Liang Y, Zhu X, et al. Fibroblast mTOR\/PPAR\u03b3\/HGF axis protects against tubular cell death and acute kidney injury. Cell Death Differ. 2019;26:2774\u201389. https:\/\/doi.org\/10.1038\/s41418-019-0336-3.","journal-title":"Cell Death Differ"},{"key":"4260_CR34","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/s0960-9822(03)00506-2","volume":"13","author":"AR Tee","year":"2003","unstructured":"Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward rheb. Curr Biol. 2003;13:1259\u201368. https:\/\/doi.org\/10.1016\/s0960-9822(03)00506-2.","journal-title":"Curr Biol"},{"key":"4260_CR35","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41419-020-2539-4","volume":"11","author":"Q Lu","year":"2020","unstructured":"Lu Q, Wang M, Gui Y, Hou Q, Gu M, Liang Y, et al. Rheb1 protects against cisplatin-induced tubular cell death and acute kidney injury via maintaining mitochondrial homeostasis. Cell Death Dis. 2020;11:364. https:\/\/doi.org\/10.1038\/s41419-020-2539-4.","journal-title":"Cell Death Dis"},{"key":"4260_CR36","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1042\/cs20180348","volume":"132","author":"J Shen","year":"2018","unstructured":"Shen J, Cui ZK, Yao F, Li K, Zhang Y, Chen Z, et al. TSC1 deletion in fibroblasts alleviates lipopolysaccharide-induced acute kidney injury. Clin Sci (Lond). 2018;132:2087\u2013101. https:\/\/doi.org\/10.1042\/cs20180348.","journal-title":"Clin Sci (Lond)"},{"key":"4260_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.kint.2019.02.009","volume":"96","author":"A Pefanis","year":"2019","unstructured":"Pefanis A, Ierino FL, Murphy JM, Cowan PJ. Regulated necrosis in kidney ischemia-reperfusion injury. Kidney Int. 2019;96:291\u2013301. https:\/\/doi.org\/10.1016\/j.kint.2019.02.009.","journal-title":"Kidney Int"},{"key":"4260_CR38","doi-asserted-by":"publisher","first-page":"eabm0142","DOI":"10.1126\/sciadv.abm0142","volume":"8","author":"A Lau","year":"2022","unstructured":"Lau A, Rahn JJ, Chappellaz M, Chung H, Benediktsson H, Bihan D, et al. Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury. Sci Adv. 2022;8:eabm0142. https:\/\/doi.org\/10.1126\/sciadv.abm0142.","journal-title":"Sci Adv"},{"key":"4260_CR39","doi-asserted-by":"publisher","first-page":"637335","DOI":"10.3389\/fimmu.2021.637335","volume":"12","author":"X Hu","year":"2021","unstructured":"Hu X, Xu Y, Zhang Z, Tang Z, Zhang J, Luo Y, et al. TSC1 affects the process of renal Ischemia-Reperfusion injury by controlling macrophage polarization. Front Immunol. 2021;12:637335. https:\/\/doi.org\/10.3389\/fimmu.2021.637335.","journal-title":"Front Immunol"},{"key":"4260_CR40","doi-asserted-by":"publisher","unstructured":"Zhou Q, Quirk JD, Hu Y, Yan H, Gaut JP, Pham CTN, et al. Rapamycin perfluorocarbon nanoparticle mitigates Cisplatin-Induced acute kidney injury. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24076086.","DOI":"10.3390\/ijms24076086"},{"key":"4260_CR41","doi-asserted-by":"publisher","first-page":"118284","DOI":"10.1016\/j.lfs.2020.118284","volume":"259","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang H, Pang T, Zuo Z, Ren K. Rapamycin improves renal injury induced by Iodixanol in diabetic rats by deactivating the mTOR\/p70S6K signaling pathway. Life Sci. 2020;259:118284. https:\/\/doi.org\/10.1016\/j.lfs.2020.118284.","journal-title":"Life Sci"},{"key":"4260_CR42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12967-014-0224-z","volume":"12","author":"C Zhang","year":"2014","unstructured":"Zhang C, Zheng L, Li L, Wang L, Li L, Huang S, et al. Rapamycin protects kidney against ischemia reperfusion injury through recruitment of NKT cells. J Transl Med. 2014;12:224. https:\/\/doi.org\/10.1186\/s12967-014-0224-z.","journal-title":"J Transl Med"},{"key":"4260_CR43","doi-asserted-by":"publisher","unstructured":"Namwanje M, Bisunke B, Rousselle TV, Lamanilao GG, Sunder VS, Patterson EC, et al. Rapamycin alternatively modifies mitochondrial dynamics in dendritic cells to reduce kidney ischemic reperfusion injury. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22105386.","DOI":"10.3390\/ijms22105386"},{"key":"4260_CR44","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/s0140-6736(19)32977-0","volume":"395","author":"P Cockwell","year":"2020","unstructured":"Cockwell P, Fisher LA. The global burden of chronic kidney disease. Lancet. 2020;395:662\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(19)32977-0.","journal-title":"Lancet"},{"key":"4260_CR45","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/s0140-6736(18)32279-7","volume":"392","author":"regional Global","year":"2018","unstructured":"Global regional. National incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789\u2013858. https:\/\/doi.org\/10.1016\/s0140-6736(18)32279-7.","journal-title":"Lancet"},{"key":"4260_CR46","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296\u2013305. https:\/\/doi.org\/10.1056\/NEJMoa041031.","journal-title":"N Engl J Med"},{"key":"4260_CR47","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-physiol-022516-034227","volume":"80","author":"BD Humphreys","year":"2018","unstructured":"Humphreys BD. Mechanisms of renal fibrosis. Annu Rev Physiol. 2018;80:309\u201326. https:\/\/doi.org\/10.1146\/annurev-physiol-022516-034227.","journal-title":"Annu Rev Physiol"},{"key":"4260_CR48","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.kint.2017.09.033","volume":"93","author":"BC Liu","year":"2018","unstructured":"Liu BC, Tang TT, Lv LL, Lan HY. Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int. 2018;93:568\u201379. https:\/\/doi.org\/10.1016\/j.kint.2017.09.033.","journal-title":"Kidney Int"},{"key":"4260_CR49","doi-asserted-by":"publisher","first-page":"616747","DOI":"10.3389\/fcell.2020.616747","volume":"8","author":"W Liu","year":"2020","unstructured":"Liu W, Yi Y, Zhang C, Zhou B, Liao L, Liu W, et al. The expression of TRIM6 activates the mTORC1 pathway by regulating the ubiquitination of TSC1-TSC2 to promote renal fibrosis. Front Cell Dev Biol. 2020;8:616747. https:\/\/doi.org\/10.3389\/fcell.2020.616747.","journal-title":"Front Cell Dev Biol"},{"key":"4260_CR50","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.kint.2020.03.035","volume":"98","author":"H Cao","year":"2020","unstructured":"Cao H, Luo J, Zhang Y, Mao X, Wen P, Ding H, et al. Tuberous sclerosis 1 (Tsc1) mediated mTORC1 activation promotes Glycolysis in tubular epithelial cells in kidney fibrosis. Kidney Int. 2020;98:686\u201398. https:\/\/doi.org\/10.1016\/j.kint.2020.03.035.","journal-title":"Kidney Int"},{"key":"4260_CR51","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1681\/asn.2014121264","volume":"27","author":"H Wu","year":"2016","unstructured":"Wu H, Chen J, Xu J, Dong Z, Meyuhas O, Chen JK. Blocking rpS6 phosphorylation exacerbates Tsc1 Deletion-Induced kidney growth. J Am Soc Nephrol. 2016;27:1145\u201358. https:\/\/doi.org\/10.1681\/asn.2014121264.","journal-title":"J Am Soc Nephrol"},{"key":"4260_CR52","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.2147\/ijn.S299969","volume":"16","author":"J Jin","year":"2021","unstructured":"Jin J, Qian F, Zheng D, He W, Gong J, He Q. Mesenchymal stem cells attenuate renal fibrosis via Exosomes-Mediated delivery of MicroRNA Let-7i-5p Antagomir. Int J Nanomed. 2021;16:3565\u201378. https:\/\/doi.org\/10.2147\/ijn.S299969.","journal-title":"Int J Nanomed"},{"key":"4260_CR53","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3111\/13696998.2015.1075995","volume":"18","author":"F Vekeman","year":"2015","unstructured":"Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, van Waalwijk van Doorn-Khosrovani SB, et al. Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs. J Med Econ. 2015;18:1060\u201370. https:\/\/doi.org\/10.3111\/13696998.2015.1075995.","journal-title":"J Med Econ"},{"key":"4260_CR54","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1053\/j.ajkd.2015.05.016","volume":"66","author":"MJ Eijkemans","year":"2015","unstructured":"Eijkemans MJ, van der Wal W, Reijnders LJ, Roes KC, van Waalwijk van Doorn-Khosrovani SB, Pelletier C, et al. Long-term Follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands. Am J Kidney Dis. 2015;66:638\u201345. https:\/\/doi.org\/10.1053\/j.ajkd.2015.05.016.","journal-title":"Am J Kidney Dis"},{"key":"4260_CR55","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s00467-018-4003-6","volume":"33","author":"P Janssens","year":"2018","unstructured":"Janssens P, Van Hoeve K, De Waele L, De Rechter S, Claes KJ, Van de Perre E, et al. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. Pediatr Nephrol. 2018;33:2085\u201393. https:\/\/doi.org\/10.1007\/s00467-018-4003-6.","journal-title":"Pediatr Nephrol"},{"key":"4260_CR56","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1586\/era.11.93","volume":"11","author":"DN Franz","year":"2011","unstructured":"Franz DN. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev Anticancer Ther. 2011;11:1181\u201392. https:\/\/doi.org\/10.1586\/era.11.93.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4260_CR57","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/btt.S25095","volume":"7","author":"DN Franz","year":"2013","unstructured":"Franz DN. Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics. 2013;7:211\u201321. https:\/\/doi.org\/10.2147\/btt.S25095.","journal-title":"Biologics"},{"key":"4260_CR58","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1053\/j.ajkd.2023.04.016","volume":"82","author":"J Kronick","year":"2023","unstructured":"Kronick J, Gabril MY, House AA. Microscopic kidney disease in tuberous sclerosis complex and treatment with mTOR Inhibition. Am J Kidney Dis. 2023;82:772\u20135. https:\/\/doi.org\/10.1053\/j.ajkd.2023.04.016.","journal-title":"Am J Kidney Dis"},{"key":"4260_CR59","doi-asserted-by":"publisher","first-page":"8637138","DOI":"10.1155\/2017\/8637138","volume":"2017","author":"C Qi","year":"2017","unstructured":"Qi C, Mao X, Zhang Z, Wu H. Classification and differential diagnosis of diabetic nephropathy. J Diabetes Res. 2017;2017:8637138. https:\/\/doi.org\/10.1155\/2017\/8637138.","journal-title":"J Diabetes Res"},{"key":"4260_CR60","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3724\/abbs.2021016","volume":"54","author":"X Li","year":"2022","unstructured":"Li X, Lu L, Hou W, Huang T, Chen X, Qi J, et al. Epigenetics in the pathogenesis of diabetic nephropathy. Acta Biochim Biophys Sin (Shanghai). 2022;54:163\u201372. https:\/\/doi.org\/10.3724\/abbs.2021016.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"4260_CR61","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2337\/diacare.28.1.164","volume":"28","author":"JL Gross","year":"2005","unstructured":"Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164\u201376. https:\/\/doi.org\/10.2337\/diacare.28.1.164.","journal-title":"Diabetes Care"},{"key":"4260_CR62","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1681\/asn.2015010032","volume":"27","author":"Y Yao","year":"2016","unstructured":"Yao Y, Wang J, Yoshida S, Nada S, Okada M, Inoki K. Role of ragulator in the regulation of mechanistic target of Rapamycin signaling in podocytes and glomerular function. J Am Soc Nephrol. 2016;27:3653\u201365. https:\/\/doi.org\/10.1681\/asn.2015010032.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"4260_CR63","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.diabres.2008.09.028","volume":"82","author":"K Inoki","year":"2008","unstructured":"Inoki K. Role of TSC-mTOR pathway in diabetic nephropathy. Diabetes Res Clin Pract. 2008;82(Suppl 1):S59\u201362. https:\/\/doi.org\/10.1016\/j.diabres.2008.09.028.","journal-title":"Diabetes Res Clin Pract"},{"key":"4260_CR64","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1083\/jcb.200403069","volume":"166","author":"LS Harrington","year":"2004","unstructured":"Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004;166:213\u201323. https:\/\/doi.org\/10.1083\/jcb.200403069.","journal-title":"J Cell Biol"},{"key":"4260_CR65","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1172\/jci44774","volume":"121","author":"M G\u00f6del","year":"2011","unstructured":"G\u00f6del M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011;121:2197\u2013209. https:\/\/doi.org\/10.1172\/jci44774.","journal-title":"J Clin Invest"},{"key":"4260_CR66","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1093\/hmg\/ddp398","volume":"18","author":"J Zhou","year":"2009","unstructured":"Zhou J, Brugarolas J, Parada LF. Loss of Tsc1, but not pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Hum Mol Genet. 2009;18:4428\u201341. https:\/\/doi.org\/10.1093\/hmg\/ddp398.","journal-title":"Hum Mol Genet"},{"key":"4260_CR67","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/sj.ki.5000161","volume":"69","author":"MJ Wu","year":"2006","unstructured":"Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int. 2006;69:2029\u201336. https:\/\/doi.org\/10.1038\/sj.ki.5000161.","journal-title":"Kidney Int"},{"key":"4260_CR68","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.apsb.2015.07.009","volume":"6","author":"F Yao","year":"2016","unstructured":"Yao F, Zhang M, Chen L. 5\u2019-Monophosphate-activated protein kinase (AMPK) improves autophagic activity in diabetes and diabetic complications. Acta Pharm Sin B. 2016;6:20\u20135. https:\/\/doi.org\/10.1016\/j.apsb.2015.07.009.","journal-title":"Acta Pharm Sin B"},{"key":"4260_CR69","doi-asserted-by":"publisher","first-page":"F588","DOI":"10.1152\/ajprenal.00472.2010","volume":"301","author":"CL Buller","year":"2011","unstructured":"Buller CL, Heilig CW, Brosius FC. 3rd. GLUT1 enhances mTOR activity independently of TSC2 and AMPK. Am J Physiol Ren Physiol. 2011;301:F588\u2013596. https:\/\/doi.org\/10.1152\/ajprenal.00472.2010.","journal-title":"Am J Physiol Ren Physiol"},{"key":"4260_CR70","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000106782","volume":"27","author":"Y Yang","year":"2007","unstructured":"Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol. 2007;27:495\u2013502. https:\/\/doi.org\/10.1159\/000106782.","journal-title":"Am J Nephrol"},{"key":"4260_CR71","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1089\/ars.2021.0217","volume":"37","author":"A Abou Daher","year":"2022","unstructured":"Abou Daher A, Alkhansa S, Azar WS, Rafeh R, Ghadieh HE, Eid AA. Translational aspects of the mammalian target of Rapamycin complexes in diabetic nephropathy. Antioxid Redox Signal. 2022;37:802\u201319. https:\/\/doi.org\/10.1089\/ars.2021.0217.","journal-title":"Antioxid Redox Signal"},{"key":"4260_CR72","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1172\/jci44771","volume":"121","author":"K Inoki","year":"2011","unstructured":"Inoki K, Mori H, Wang J, Suzuki T, Hong S, Yoshida S, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011;121:2181\u201396. https:\/\/doi.org\/10.1172\/jci44771.","journal-title":"J Clin Invest"},{"key":"4260_CR73","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1007\/s00467-022-05820-x","volume":"38","author":"S Gallo-Bernal","year":"2023","unstructured":"Gallo-Bernal S, Kilcoyne A, Gee MS, Paul E. Cystic kidney disease in tuberous sclerosis complex: current knowledge and unresolved questions. Pediatr Nephrol. 2023;38:3253\u201364. https:\/\/doi.org\/10.1007\/s00467-022-05820-x.","journal-title":"Pediatr Nephrol"},{"key":"4260_CR74","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3389\/fneur.2020.00972","volume":"11","author":"JC Kingswood","year":"2020","unstructured":"Kingswood JC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. Renal manifestations of tuberous sclerosis complex: key findings from the final analysis of the TOSCA study focussing mainly on renal angiomyolipomas. Front Neurol. 2020;11:972. https:\/\/doi.org\/10.3389\/fneur.2020.00972.","journal-title":"Front Neurol"},{"key":"4260_CR75","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/ki.2010.457","volume":"79","author":"TB Huber","year":"2011","unstructured":"Huber TB, Walz G, Kuehn EW. mTOR and Rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int. 2011;79:502\u201311. https:\/\/doi.org\/10.1038\/ki.2010.457.","journal-title":"Kidney Int"},{"key":"4260_CR76","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1158\/0008-5472.Can-06-1740","volume":"66","author":"C Wilson","year":"2006","unstructured":"Wilson C, Bonnet C, Guy C, Idziaszczyk S, Colley J, Humphreys V, et al. Tsc1 haploinsufficiency without mammalian target of Rapamycin activation is sufficient for renal cyst formation in Tsc1+\/- mice. Cancer Res. 2006;66:7934\u20138. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-1740.","journal-title":"Cancer Res"},{"key":"4260_CR77","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41420-020-0285-0","volume":"6","author":"Y Fang","year":"2020","unstructured":"Fang Y, Li F, Qi C, Mao X, Wang F, Zhao Z, et al. Metformin effectively treats Tsc1 deletion-caused kidney pathology by upregulating AMPK phosphorylation. Cell Death Discov. 2020;6:52. https:\/\/doi.org\/10.1038\/s41420-020-0285-0.","journal-title":"Cell Death Discov"},{"key":"4260_CR78","doi-asserted-by":"publisher","first-page":"e0197973","DOI":"10.1371\/journal.pone.0197973","volume":"13","author":"R Centini","year":"2018","unstructured":"Centini R, Tsang M, Iwata T, Park H, Delrow J, Margineantu D, et al. Loss of Fnip1 alters kidney developmental transcriptional program and synergizes with TSC1 loss to promote mTORC1 activation and renal cyst formation. PLoS ONE. 2018;13:e0197973. https:\/\/doi.org\/10.1371\/journal.pone.0197973.","journal-title":"PLoS ONE"},{"key":"4260_CR79","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/labinvest.2017.97","volume":"97","author":"X Nie","year":"2017","unstructured":"Nie X, Arend LJ. Deletion of Pkd1 in renal stromal cells causes defects in the renal stromal compartment and progressive cystogenesis in the kidney. Lab Invest. 2017;97:1427\u201338. https:\/\/doi.org\/10.1038\/labinvest.2017.97.","journal-title":"Lab Invest"},{"key":"4260_CR80","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41598-018-37139-9","volume":"9","author":"Z Wu","year":"2019","unstructured":"Wu Z, Wu H, Md S, Yu G, Habib SL, Li B, et al. Tsc1 ablation in Prx1 and Osterix lineages causes renal cystogenesis in mouse. Sci Rep. 2019;9:837. https:\/\/doi.org\/10.1038\/s41598-018-37139-9.","journal-title":"Sci Rep"},{"key":"4260_CR81","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1172\/jci20665","volume":"113","author":"SR Blomqvist","year":"2004","unstructured":"Blomqvist SR, Vidarsson H, Fitzgerald S, Johansson BR, Ollerstam A, Brown R, et al. Distal renal tubular acidosis in mice that lack the forkhead transcription factor Foxi1. J Clin Invest. 2004;113:1560\u201370. https:\/\/doi.org\/10.1172\/jci20665.","journal-title":"J Clin Invest"},{"key":"4260_CR82","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.celrep.2017.07.043","volume":"20","author":"D Lindgren","year":"2017","unstructured":"Lindgren D, Eriksson P, Krawczyk K, Nilsson H, Hansson J, Veerla S, et al. Cell-Type-Specific gene programs of the normal human nephron define kidney Cancer subtypes. Cell Rep. 2017;20:1476\u201389. https:\/\/doi.org\/10.1016\/j.celrep.2017.07.043.","journal-title":"Cell Rep"},{"key":"4260_CR83","doi-asserted-by":"publisher","first-page":"e4471","DOI":"10.1371\/journal.pone.0004471","volume":"4","author":"H Vidarsson","year":"2009","unstructured":"Vidarsson H, Westergren R, Heglind M, Blomqvist SR, Breton S, Enerb\u00e4ck S. The forkhead transcription factor Foxi1 is a master regulator of vacuolar H-ATPase proton pump subunits in the inner ear, kidney and epididymis. PLoS ONE. 2009;4:e4471. https:\/\/doi.org\/10.1371\/journal.pone.0004471.","journal-title":"PLoS ONE"},{"key":"4260_CR84","doi-asserted-by":"publisher","first-page":"1289388","DOI":"10.3389\/fphys.2023.1289388","volume":"14","author":"M Soleimani","year":"2023","unstructured":"Soleimani M. Not all kidney cysts are created equal: a distinct renal cystogenic mechanism in tuberous sclerosis complex (TSC). Front Physiol. 2023;14:1289388. https:\/\/doi.org\/10.3389\/fphys.2023.1289388.","journal-title":"Front Physiol"},{"key":"4260_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.braindev.2018.07.003","volume":"41","author":"M Mizuguchi","year":"2019","unstructured":"Mizuguchi M, Ikeda H, Kagitani-Shimono K, Yoshinaga H, Suzuki Y, Aoki M, et al. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. Brain Dev. 2019;41:1\u201310. https:\/\/doi.org\/10.1016\/j.braindev.2018.07.003.","journal-title":"Brain Dev"},{"key":"4260_CR86","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/s0140-6736(12)61767-x","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for Angiomyolipoma associated with tuberous sclerosis complex or sporadic Lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:817\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(12)61767-x.","journal-title":"Lancet"},{"key":"4260_CR87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","volume":"153","author":"M Wataya-Kaneda","year":"2017","unstructured":"Wataya-Kaneda M, Nakamura A, Tanaka M, Hayashi M, Matsumoto S, Yamamoto K, et al. Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: A randomized clinical trial. JAMA Dermatol. 2017;153:39\u201348. https:\/\/doi.org\/10.1001\/jamadermatol.2016.3545.","journal-title":"JAMA Dermatol"},{"key":"4260_CR88","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/s0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell Astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381:125\u201332. https:\/\/doi.org\/10.1016\/s0140-6736(12)61134-9.","journal-title":"Lancet"},{"key":"4260_CR89","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12882-024-03743-3","volume":"25","author":"S Banerjee","year":"2024","unstructured":"Banerjee S, Feldenberg LR. Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series. BMC Nephrol. 2024;25:376. https:\/\/doi.org\/10.1186\/s12882-024-03743-3.","journal-title":"BMC Nephrol"},{"key":"4260_CR90","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000104818","volume":"30","author":"M Wu","year":"2007","unstructured":"Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res. 2007;30:253\u20139. https:\/\/doi.org\/10.1159\/000104818.","journal-title":"Kidney Blood Press Res"},{"key":"4260_CR91","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"4260_CR92","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.eururo.2017.06.040","volume":"72","author":"RH Giles","year":"2017","unstructured":"Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, et al. Recommendations for the management of rare kidney cancers. Eur Urol. 2017;72:974\u201383. https:\/\/doi.org\/10.1016\/j.eururo.2017.06.040.","journal-title":"Eur Urol"},{"key":"4260_CR93","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/his.14816","volume":"82","author":"SR Williamson","year":"2023","unstructured":"Williamson SR, Hes O, Trpkov K, Aggarwal A, Satapathy A, Mishra S, et al. Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity. Histopathology. 2023;82:296\u2013304. https:\/\/doi.org\/10.1111\/his.14816.","journal-title":"Histopathology"},{"key":"4260_CR94","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00428-023-03673-9","volume":"483","author":"C Ricci","year":"2023","unstructured":"Ricci C, Ambrosi F, Franceschini T, Giunchi F, Grillini A, Franchini E, et al. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT. Virchows Arch. 2023;483:687\u201398. https:\/\/doi.org\/10.1007\/s00428-023-03673-9.","journal-title":"Virchows Arch"},{"key":"4260_CR95","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/10668969231178032","volume":"32","author":"SE Siegmund","year":"2024","unstructured":"Siegmund SE, Al-Obaidy KI, Tsai HK, Idrees MT, Akgul M, Acosta AM, et al. Concordance of MTOR pathway mutations and the diagnosis of renal Low-Grade oncocytic tumor (LOT). Int J Surg Pathol. 2024;32:316\u201330. https:\/\/doi.org\/10.1177\/10668969231178032.","journal-title":"Int J Surg Pathol"},{"key":"4260_CR96","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/jci7319","volume":"104","author":"H Onda","year":"1999","unstructured":"Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ. Tsc2(+\/-) mice develop tumors in multiple sites that express Gelsolin and are influenced by genetic background. J Clin Invest. 1999;104:687\u201395. https:\/\/doi.org\/10.1172\/jci7319.","journal-title":"J Clin Invest"},{"key":"4260_CR97","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1172\/jci128287","volume":"129","author":"K Asrani","year":"2019","unstructured":"Asrani K, Murali S, Lam B, Na CH, Phatak P, Sood A, et al. mTORC1 feedback to AKT modulates lysosomal biogenesis through mit\/tfe regulation. J Clin Invest. 2019;129:5584\u201399. https:\/\/doi.org\/10.1172\/jci128287.","journal-title":"J Clin Invest"},{"key":"4260_CR98","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1097\/PAS.0b013e3181e8ce5b","volume":"34","author":"P Argani","year":"2010","unstructured":"Argani P, Hicks J, De Marzo AM, Albadine R, Illei PB, Ladanyi M, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34:1295\u2013303. https:\/\/doi.org\/10.1097\/PAS.0b013e3181e8ce5b.","journal-title":"Am J Surg Pathol"},{"key":"4260_CR99","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/path.5875","volume":"257","author":"DC Salles","year":"2022","unstructured":"Salles DC, Asrani K, Woo J, Vidotto T, Liu HB, Vidal I, et al. GPNMB expression identifies TSC1\/2\/mTOR-associated and MiT family translocation-driven renal neoplasms. J Pathol. 2022;257:158\u201371. https:\/\/doi.org\/10.1002\/path.5875.","journal-title":"J Pathol"},{"key":"4260_CR100","first-page":"1201","volume":"149","author":"J Bjornsson","year":"1996","unstructured":"Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol. 1996;149:1201\u20138.","journal-title":"Am J Pathol"},{"key":"4260_CR101","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.ki.5001853","volume":"70","author":"SK Rakowski","year":"2006","unstructured":"Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int. 2006;70:1777\u201382. https:\/\/doi.org\/10.1038\/sj.ki.5001853.","journal-title":"Kidney Int"},{"key":"4260_CR102","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271\u201381. https:\/\/doi.org\/10.1056\/NEJMoa066838.","journal-title":"N Engl J Med"},{"key":"4260_CR103","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256\u201365. https:\/\/doi.org\/10.1002\/cncr.25219.","journal-title":"Cancer"},{"key":"4260_CR104","doi-asserted-by":"publisher","unstructured":"Alsidawi S, Kasi PM. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma. Cold Spring Harb Mol Case Stud. 2018;4. https:\/\/doi.org\/10.1101\/mcs.a002220.","DOI":"10.1101\/mcs.a002220"},{"key":"4260_CR105","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1752-1947-8-95","volume":"8","author":"HS Kim","year":"2014","unstructured":"Kim HS, Kim ST, Kang SH, Sung DJ, Kim CH, Shin SW, et al. The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report. J Med Case Rep. 2014;8:95. https:\/\/doi.org\/10.1186\/1752-1947-8-95.","journal-title":"J Med Case Rep"},{"key":"4260_CR106","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/pbc.22401","volume":"54","author":"JG Pressey","year":"2010","unstructured":"Pressey JG, Wright JM, Geller JI, Joseph DB, Pressey CS, Kelly DR. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 2010;54:1035\u20137. https:\/\/doi.org\/10.1002\/pbc.22401.","journal-title":"Pediatr Blood Cancer"},{"key":"4260_CR107","doi-asserted-by":"publisher","first-page":"151","DOI":"10.6004\/jnccn.2015.0022","volume":"13","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015;13:151\u20139. https:\/\/doi.org\/10.6004\/jnccn.2015.0022.","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 3","key":"4260_CR108","doi-asserted-by":"publisher","first-page":"iii49","DOI":"10.1093\/annonc\/mdu259","volume":"25","author":"B Escudier","year":"2014","unstructured":"Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii49\u201356. https:\/\/doi.org\/10.1093\/annonc\/mdu259.","journal-title":"Ann Oncol"},{"key":"4260_CR109","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced Renal-Cell carcinoma. N Engl J Med. 2015;373:1803\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1510665.","journal-title":"N Engl J Med"},{"key":"4260_CR110","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced Renal-Cell carcinoma. N Engl J Med. 2015;373:1814\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1510016.","journal-title":"N Engl J Med"},{"key":"4260_CR111","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1053\/j.semdp.2015.02.006","volume":"32","author":"G Martignoni","year":"2015","unstructured":"Martignoni G, Pea M, Zampini C, Brunelli M, Segala D, Zamboni G, et al. PEComas of the kidney and of the genitourinary tract. Semin Diagn Pathol. 2015;32:140\u201359. https:\/\/doi.org\/10.1053\/j.semdp.2015.02.006.","journal-title":"Semin Diagn Pathol"},{"key":"4260_CR112","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0002-9440(10)63843-6","volume":"162","author":"M Karbowniczek","year":"2003","unstructured":"Karbowniczek M, Yu J, Henske EP. Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Pathol. 2003;162:491\u2013500. https:\/\/doi.org\/10.1016\/s0002-9440(10)63843-6.","journal-title":"Am J Pathol"},{"key":"4260_CR113","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/s0046-8177(98)90414-2","volume":"29","author":"V Paradis","year":"1998","unstructured":"Paradis V, Laurendeau I, Vieillefond A, Blanchet P, Eschwege P, Beno\u00eet G, et al. Clonal analysis of renal sporadic angiomyolipomas. Hum Pathol. 1998;29:1063\u20137. https:\/\/doi.org\/10.1016\/s0046-8177(98)90414-2.","journal-title":"Hum Pathol"},{"key":"4260_CR114","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-4632.2010.04727.x","volume":"50","author":"J Borkowska","year":"2011","unstructured":"Borkowska J, Schwartz RA, Kotulska K, Jozwiak S. Tuberous sclerosis complex: tumors and tumorigenesis. Int J Dermatol. 2011;50:13\u201320. https:\/\/doi.org\/10.1111\/j.1365-4632.2010.04727.x.","journal-title":"Int J Dermatol"},{"key":"4260_CR115","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s41467-017-01514-3","volume":"8","author":"AF Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves AF, Adlesic M, Brandt S, Hejhal T, Harlander S, Sommer L, et al. Evidence of renal Angiomyolipoma neoplastic stem cells arising from renal epithelial cells. Nat Commun. 2017;8:1466. https:\/\/doi.org\/10.1038\/s41467-017-01514-3.","journal-title":"Nat Commun"},{"key":"4260_CR116","doi-asserted-by":"publisher","first-page":"e1006242","DOI":"10.1371\/journal.pgen.1006242","volume":"12","author":"K Giannikou","year":"2016","unstructured":"Giannikou K, Malinowska IA, Pugh TJ, Yan R, Tseng YY, Oh C, et al. Whole exome sequencing identifies TSC1\/TSC2 biallelic loss as the primary and sufficient driver event for renal Angiomyolipoma development. PLoS Genet. 2016;12:e1006242. https:\/\/doi.org\/10.1371\/journal.pgen.1006242.","journal-title":"PLoS Genet"},{"key":"4260_CR117","doi-asserted-by":"publisher","first-page":"15816","DOI":"10.1038\/ncomms15816","volume":"8","author":"KR Martin","year":"2017","unstructured":"Martin KR, Zhou W, Bowman MJ, Shih J, Au KS, Dittenhafer-Reed KE, et al. The genomic landscape of tuberous sclerosis complex. Nat Commun. 2017;8:15816. https:\/\/doi.org\/10.1038\/ncomms15816.","journal-title":"Nat Commun"},{"key":"4260_CR118","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1086\/301804","volume":"62","author":"TA Smolarek","year":"1998","unstructured":"Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 1998;62:810\u20135. https:\/\/doi.org\/10.1086\/301804.","journal-title":"Am J Hum Genet"},{"key":"4260_CR119","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41388-020-01504-8","volume":"40","author":"M Zarei","year":"2021","unstructured":"Zarei M, Giannikou K, Du H, Liu HJ, Duarte M, Johnson S, et al. MITF is a driver oncogene and potential therapeutic target in kidney Angiomyolipoma tumors through transcriptional regulation of CYR61. Oncogene. 2021;40:112\u201326. https:\/\/doi.org\/10.1038\/s41388-020-01504-8.","journal-title":"Oncogene"},{"key":"4260_CR120","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:255\u201365. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2013.08.002.","journal-title":"Pediatr Neurol"},{"key":"4260_CR121","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00292-020-00901-w","volume":"42","author":"D Theegarten","year":"2021","unstructured":"Theegarten D, Hager T. [Pulmonary Lymphangioleiomyomatosis (LAM)]. Pathologe. 2021;42:35\u20139. https:\/\/doi.org\/10.1007\/s00292-020-00901-w.","journal-title":"Pathologe"},{"key":"4260_CR122","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfv249","volume":"31","author":"JJ Bissler","year":"2016","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for renal Angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transpl. 2016;31:111\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfv249.","journal-title":"Nephrol Dial Transpl"},{"key":"4260_CR123","doi-asserted-by":"publisher","first-page":"871723","DOI":"10.3389\/fonc.2022.871723","volume":"12","author":"W Wang","year":"2022","unstructured":"Wang W, Guo G, Shi G, Wei X, Hu Z, Li H, et al. A Multi-Centric study assessing safety and efficacy of everolimus in adult Chinese patients with tuberous sclerosis complex associated renal angiomyolipomas. Front Oncol. 2022;12:871723. https:\/\/doi.org\/10.3389\/fonc.2022.871723.","journal-title":"Front Oncol"},{"key":"4260_CR124","doi-asserted-by":"publisher","first-page":"e1099","DOI":"10.1016\/j.clgc.2019.07.005","volume":"17","author":"G Guo","year":"2019","unstructured":"Guo G, Gu L, Zhang X. Application of everolimus in preoperative neoadjuvant therapy of tuberous sclerosis complex associated with renal angiomyolipoma: A Single-Center report of 5 cases. Clin Genitourin Cancer. 2019;17:e1099\u2013103. https:\/\/doi.org\/10.1016\/j.clgc.2019.07.005.","journal-title":"Clin Genitourin Cancer"},{"key":"4260_CR125","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13023-018-0781-y","volume":"13","author":"Y Cai","year":"2018","unstructured":"Cai Y, Guo H, Wang W, Li H, Sun H, Shi B, et al. Assessing the outcomes of everolimus on renal Angiomyolipoma associated with tuberous sclerosis complex in china: a two years trial. Orphanet J Rare Dis. 2018;13:43. https:\/\/doi.org\/10.1186\/s13023-018-0781-y.","journal-title":"Orphanet J Rare Dis"},{"key":"4260_CR126","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.3892\/ol.2017.7079","volume":"14","author":"S Li","year":"2017","unstructured":"Li S, Zhang Y, Wei J, Zhang X. Clinical and genetic analysis of tuberous sclerosis complex-associated renal Angiomyolipoma in Chinese pedigrees. Oncol Lett. 2017;14:7085\u201390. https:\/\/doi.org\/10.3892\/ol.2017.7079.","journal-title":"Oncol Lett"},{"key":"4260_CR127","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s13023-023-02982-1","volume":"18","author":"I Cockerell","year":"2023","unstructured":"Cockerell I, Christensen J, Hoei-Hansen CE, Holst L, Grenaa Frederiksen M, Issa-Epe AI, et al. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice. Orphanet J Rare Dis. 2023;18:377. https:\/\/doi.org\/10.1186\/s13023-023-02982-1.","journal-title":"Orphanet J Rare Dis"},{"key":"4260_CR128","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13023-016-0517-9","volume":"11","author":"NR Robles","year":"2016","unstructured":"Robles NR, Peces R, G\u00f3mez-Ferrer \u00c1, Villacampa F, \u00c1lvarez-Ossorio JL, P\u00e9rez-Segura P, et al. Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. Orphanet J Rare Dis. 2016;11:128. https:\/\/doi.org\/10.1186\/s13023-016-0517-9.","journal-title":"Orphanet J Rare Dis"},{"key":"4260_CR129","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/ckj\/sfac037","volume":"15","author":"NKX Chung","year":"2022","unstructured":"Chung NKX, Metherall P, McCormick JA, Simms RJ, Ong. A C M. Individualized everolimus treatment for tuberous sclerosis-related Angiomyolipoma promotes treatment adherence and response. Clin Kidney J. 2022;15:1160\u20138. https:\/\/doi.org\/10.1093\/ckj\/sfac037.","journal-title":"Clin Kidney J"},{"key":"4260_CR130","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/ndt\/gfy132","volume":"34","author":"JJ Bissler","year":"2019","unstructured":"Bissler JJ, Budde K, Sauter M, Franz DN, Zonnenberg BA, Frost MD, et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrol Dial Transpl. 2019;34:1000\u20138. https:\/\/doi.org\/10.1093\/ndt\/gfy132.","journal-title":"Nephrol Dial Transpl"},{"key":"4260_CR131","doi-asserted-by":"publisher","first-page":"e0204646","DOI":"10.1371\/journal.pone.0204646","volume":"13","author":"BA Zonnenberg","year":"2018","unstructured":"Zonnenberg BA, Neary MP, Duh MS, Ionescu-Ittu R, Fortier J, Vekeman F. Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal Angiomyolipoma treated with everolimus. PLoS ONE. 2018;13:e0204646. https:\/\/doi.org\/10.1371\/journal.pone.0204646.","journal-title":"PLoS ONE"},{"key":"4260_CR132","doi-asserted-by":"publisher","first-page":"610858","DOI":"10.3389\/fonc.2020.610858","volume":"10","author":"G Guo","year":"2020","unstructured":"Guo G, Gu L, Zhang X. Everolimus in invasive malignant renal epithelioid Angiomyolipoma. Front Oncol. 2020;10:610858. https:\/\/doi.org\/10.3389\/fonc.2020.610858.","journal-title":"Front Oncol"},{"key":"4260_CR133","doi-asserted-by":"publisher","first-page":"e70181","DOI":"10.1002\/cam4.70181","volume":"13","author":"R Su","year":"2024","unstructured":"Su R, Huang T, Gu L, Bao Y, Liu Z, Dao P, et al. Neoadjuvant everolimus in renal Angiomyolipoma with or without tuberous sclerosis complex: results from a multicenter, retrospective study. Cancer Med. 2024;13:e70181. https:\/\/doi.org\/10.1002\/cam4.70181.","journal-title":"Cancer Med"},{"key":"4260_CR134","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s13023-021-01932-z","volume":"16","author":"C Luo","year":"2021","unstructured":"Luo C, Zhang YS, Zhang MX, Chen MF, Li Y, Qi L, et al. Everolimus versus sirolimus for Angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China. Orphanet J Rare Dis. 2021;16:299. https:\/\/doi.org\/10.1186\/s13023-021-01932-z.","journal-title":"Orphanet J Rare Dis"},{"key":"4260_CR135","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jaad.2015.07.018","volume":"73","author":"N Nathan","year":"2015","unstructured":"Nathan N, Wang JA, Li S, Cowen EW, Haughey M, Moss J, et al. Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus. J Am Acad Dermatol. 2015;73:802\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2015.07.018.","journal-title":"J Am Acad Dermatol"},{"key":"4260_CR136","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1590\/abd1806-4841.20186972","volume":"93","author":"LKL Portocarrero","year":"2018","unstructured":"Portocarrero LKL, Quental KN, Samorano LP, Oliveira ZNP, Rivitti-Machado M. Tuberous sclerosis complex: review based on new diagnostic criteria. Bras Dermatol. 2018;93:323\u201331. https:\/\/doi.org\/10.1590\/abd1806-4841.20186972.","journal-title":"Bras Dermatol"},{"key":"4260_CR137","first-page":"812","volume":"52","author":"L Zou","year":"2014","unstructured":"Zou L, Liu Y, Pang L, Ju J, Shi Z, Zhang J, et al. [Efficacy and safety of Rapamycin in treatment of children with epilepsy complicated with tuberous sclerosis]. Zhonghua Er Ke Za Zhi. 2014;52:812\u20136.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"4260_CR138","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19:31\u20139. https:\/\/doi.org\/10.1007\/s40257-018-0384-3.","journal-title":"Am J Clin Dermatol"},{"key":"4260_CR139","doi-asserted-by":"publisher","first-page":"5715","DOI":"10.2147\/jir.S434483","volume":"16","author":"FY Yu","year":"2023","unstructured":"Yu FY, Zheng K, Wu YF, Gao SW, Weng QY, Zhu C, et al. Rapamycin exacerbates Staphylococcus aureus pneumonia by inhibiting mTOR-RPS6 in macrophages. J Inflamm Res. 2023;16:5715\u201328. https:\/\/doi.org\/10.2147\/jir.S434483.","journal-title":"J Inflamm Res"},{"key":"4260_CR140","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","volume":"10","author":"G Canaud","year":"2010","unstructured":"Canaud G, Knebelmann B, Harris PC, Vrtovsnik F, Correas JM, Pallet N, et al. Therapeutic mTOR Inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level? Am J Transpl. 2010;10:1701\u20136. https:\/\/doi.org\/10.1111\/j.1600-6143.2010.03152.x.","journal-title":"Am J Transpl"},{"key":"4260_CR141","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3265\/Nefrologia.pre2013.Jan.11439","volume":"33","author":"G Molas-Ferrer","year":"2013","unstructured":"Molas-Ferrer G, Soy-Muner D, Anglada-Mart\u00ednez H, Riu-Viladoms G, Estefanell-Tejero A, Ribas-Sala J. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors. Nefrologia. 2013;33:297\u2013300. https:\/\/doi.org\/10.3265\/Nefrologia.pre2013.Jan.11439.","journal-title":"Nefrologia"},{"key":"4260_CR142","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for Angiomyolipoma in tuberous sclerosis complex or Lymphangioleiomyomatosis. N Engl J Med. 2008;358:140\u201351. https:\/\/doi.org\/10.1056\/NEJMoa063564.","journal-title":"N Engl J Med"},{"key":"4260_CR143","doi-asserted-by":"publisher","first-page":"403280","DOI":"10.1155\/2013\/403280","volume":"2013","author":"G Zaza","year":"2013","unstructured":"Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol. 2013;2013:403280. https:\/\/doi.org\/10.1155\/2013\/403280.","journal-title":"Clin Dev Immunol"},{"key":"4260_CR144","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","volume":"17","author":"JP MacKeigan","year":"2015","unstructured":"MacKeigan JP, Krueger DA. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol. 2015;17:1550\u20139. https:\/\/doi.org\/10.1093\/neuonc\/nov152.","journal-title":"Neuro Oncol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04260-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:33:43Z","timestamp":1751366023000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04260-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4260"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04260-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None required for reviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"It does not apply to reviews.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"316"}}